# ClinicalIntelPulse FDA/EMA Approval Outlook

> ClinicalIntelPulse FDA/EMA Approval Outlook is a paid API for AI agents from clinicalintelpulse.vercel.app, paid per call via x402, $0.25/call, status unknown (last checked 2026-09-13).

Analyzes FDA/EMA approval probability for drugs in a given disease area, ranking candidates most likely to win approval in 12–18 months based on Phase 3 data, PDUFA dates, and historical trial success rates.

## Facts

- Endpoint: GET https://clinicalintelpulse.vercel.app/api/clinical/approval-outlook
- Price: $0.25/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-13
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-fda-ema-approval-outlook-be1afa8d
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_HVPb4xweGH-q51tcxOQkD

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-fda-ema-approval-outlook-be1afa8d
```

Example prompt: What drugs in the NASH space are most likely to get FDA or EMA approval in the next 12 to 18 months — give me approval probabilities ranked by strength of Phase 3 data and upcoming PDUFA dates?

## When to prefer this

Use this endpoint when you need forward-looking regulatory probability analysis for a specific disease area — particularly for biotech investment decisions, payer budget planning, or competitive pipeline monitoring. Prefer this over general pipeline endpoints when the primary need is approval likelihood ranking and PDUFA date proximity rather than broad trial counts or mechanism landscapes.

## Known failure modes

- Unrecognized or overly broad disease area input returns empty or low-confidence results
- No drugs currently in Phase 3 for the queried disease area results in sparse output
- Stale PDUFA date data if not recently refreshed, potentially affecting forecast accuracy
- Rate limiting or payment failure returns 402 error requiring retry with valid USDC payment

## How this service works

FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.

## Output

Returns a ranked list of drug candidates in the specified disease area with estimated FDA/EMA approval probabilities, upcoming PDUFA dates, Phase 3 readout timelines, and supporting trial success rate data — structured for biotech investors and payer decision-makers.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "lang": {
       "type": "string"
      },
      "agency": {
       "type": "string"
      },
      "horizon": {
       "type": "string"
      },
      "condition": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "query_summary": {
   "horizon": "18m",
   "agencies": [
    "FDA",
    "EMA"
   ],
   "condition": "Alzheimer Disease"
  },
  "market_context": "Alzheimer's is the highest-value CNS approval category. Any successful amyloid or tau therapy represents $5-15B peak sales potential.",
  "pdufa_calendar": [
   {
    "drug": "Donanemab",
    "sponsor": "Eli Lilly",
    "indication": "Early symptomatic AD",
    "pdufa_date": "2025-Q2",
    "priority_review": true
   }
  ],
  "approval_candidates": [
   {
    "drug": "Lecanemab (Leqembi)",
    "nctId": "NCT03887455",
    "sponsor": "Eisai / Biogen",
    "key_risk": "ARIA (amyloid-related imaging abnormalities) safety profile limiting real-world use",
    "mechanism": "Anti-amyloid monoclonal antibody (protofibrils)",
    "ema_status": "CHMP assessment ongoing 2025",
    "fda_status": "Full approval received 2023; expanded label applications pending",
    "trial_result": "Positive — 27% slowing of clinical decline vs placebo (p<0.001)",
    "approval_probability": 85
   }
  ],
  "approval_rate_context": {
   "rare_disease_premium": "Breakthrough therapy designation adds ~15% probability uplift",
   "us_approval_rate_phase3_pct": 58,
   "disease_area_historical_phase3_success_pct": 55
  }
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-fda-ema-approval-outlook-be1afa8d/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.vercel.app](https://www.zero.xyz/host/clinicalintelpulse.vercel.app/llms.txt)